SEHK:1672Biotechs
Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?
Ascletis Pharma recently reported positive topline results from a U.S. Phase I trial of ASC50, an in-house oral IL‑17 inhibitor for mild to moderate psoriasis, showing favorable safety, tolerability and target engagement across multiple dose levels with no serious adverse events.
The data support convenient once-daily or potentially once-weekly oral dosing and extend patent protection on this new chemical entity through 2043, underscoring a differentiated approach within the autoimmune and...